there are an increasing number of men being diagnosed and treated at a younger age. This has led to the first-degree family members of these men with prostate cancer actively seeking 'screening' for the disease and raising such issues as the possibility of genetic testing for the disease.Genet...
Men who are diagnosed with low-risk prostate cancer usually opt for active surveillance—a monitoring of their cancer over time without undergoing treatments that would cause side effects. In many men, the cancer never grows and poses no threat, but in others, the cancer begins to grow and tr...
It was not possible to adjust for all the factors ot... UK Trial of Early Detection of Breast Cancer Group - 《Breast》 被引量: 58发表: 1993年 Cancer-specific mortality in men diagnosed with prostate cancer before age 50 years, a nationwide population-based study To compare the clinical ...
population-based Prostate testing for cancer and Treatment (ProtecT) study of prostate-specific antigen-detected prostate cancer in men ages 50 to 69 years... SM Collin,C Metcalfe,H Refsum,... - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer ...
When testing for prostate cancer, as many as 75% of men with a raised prostate-specific antigen (PSA) have a benign biopsy result. Little is known about the psychological effect of this result for these men. In all, 330 men participating in the prostate
Results. - Approximately 82% of men interviewed expressed that they "probably" or"definitely" would get genetic testing for prostate cancer risk if offered now. Factoranalysis revealed four distinct, meaningful factors for intention to receive genetic testing for prostate cancer risk. These factors ...
Background: Previous quantitative studies have not compared the use of prostate and colorectal cancer (CRC) testing between gay/bisexual and heterosexual men. Methods: We analyzed cross-sectional data on 19,410 men in the California Health Interview Survey. The percentage of respondents age 50 and...
Men who have already been treated for prostate cancer, have high-risk, or metastatic prostate cancer, should consider theMyriad MyRiskgermline test. Germline testing helps men understand if they qualify for new therapies and if their families have an elevated risk of developing cancer in the ...
Research is needed to evaluate the most effective approach to assisting men in making an informed decision about whether or not to have a PSA test.The increasing incidence of and mortality from prostate cancer has led to widespread calls for prostate cancer screening. However, the subject is ...
RESULTS The overall annual rate of testing in men with no previous diagnosis of prostate cancer was estimated to be 6%, of which the annual rates of asymptomatic, symptomatic and re-testing were 2.0%, 2.8% and 1.2%, respectively, after adjusting for missing values. The rate decreased with ...